from AMOEBA (EPA:ALMIB)
AMOEBA ANNOUNCES AVAILABILITY OF UNIVERSAL REGISTRATION DOCUMENT 2023
Press release
AMOEBA ANNOUNCES AVAILABILITY OF UNIVERSAL REGISTRATION DOCUMENT 2023
Chassieu (France), April 29, 2024 – 5:45pm – AMOÉBA (FR0011051598 – ALMIB), an industrial biotech specialising in the treatment of microbiological risk, developing a biocontrol agent for the treatment of plants in agriculture and an anti-ageing cosmetic ingredient, announces that it has filed its 2023 Universal Registration Document with the Autorité des marchés financiers (AMF) on 29 April 2024 under number D.24-0352.
The Universal Registration Document 2023, covering the financial year ending 31 December 2023, includes in particular :
• 
The 2023 annual financial report, consisting of the consolidated financial statements, the annual financial statements, the management report and the related statutory auditors' reports;
• The report on corporate governance drawn up by the Board of Directors.
This document is available on the company's website at www.amoebanature.com under the heading ‘Investors/Financial information/Reference document’. Printed copies are also available from the company's head office: 38, avenue des frères Montgolfier, 69680 Chassieu, France.
About AMOÉBA:
Founded in 2010, Amoéba is a biotech based in Chassieu (Lyon, France) with the ambition to become a major player for the treatment of microbiological risk in the water, crop protection and health sectors.
Based on the natural properties of a unique microorganism, the only one of its kind in the world, our biological solutions offer a viable alternative to the chemical products that are widely used in the industry today. Amoéba is currently focused on the global biocontrol market for plant protection and the cosmetics market. As the market release of phytosanitary products is subject to local regulatory approvals, the Company has completed the regulatory processes required and in 2022 obtained approval for its active substance in the United States and its recommendation for approval in Europe, issued by the Austrian authority. As the cosmetic application does not require prior approval from a relevant authority in Europe and the United States, the party responsible for bringing the formulated cosmetic product to market must carry out a self-assessment of its safety. Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. For more information, please visit www.amoeba-nature.com.
Contacts:
Amoéba Jean-François Doucet Chief Executive Officer | Calyptus Investor & Press Relations Nicolas Hélin / Mathieu Calleux |
+33 (0)4 26 69 16 00 +33 (0)1 53 65 37 90 / 91 jf.doucet@amoeba-nature.com amoeba@calyptus.net
Address: 38 Avenue des Frères Montgolfier, 69680 Chassieu
French limited company (société anonyme) with capital of Tel: +33 (0)4 26 69 16 00 – Email: contact@amoeba-nature.com
€993,199.26 LinkedIn: @amoeba-nature – Twitter: @AmoebaNature Lyon trade and companies register: 523 877 215 www.amoeba-nature.com